Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfamethazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.88 |
| ▸ | GAA | P10253 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfamethazine SCHEMBL151305 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL17256221 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL29918086 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL28567572 | 0.92 | ALDH1A1 (0.97) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL3495558 | 0.92 | ALDH1A1 (0.97) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL1442165 | 0.92 | ALDH1A1 (0.97) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL28028309 | 0.91 | ALDH1A1 (0.94) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL11708760 | 0.90 | ALDH1A1 (0.91) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL29243922 | 0.88 | ALDH1A1 (0.88) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA | |
| Sulfamethazine SCHEMBL28447030 | 0.87 | ALDH1A1 (0.86) | ALDH1A1CYP3A4SMN1; SMN2TDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467743-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A FUNGICIDE, A BACTERIOSTATIC SULPHONAMIDE AND AN ANTIBACTERIAL COMPOUND FOR TOPICAL APPLICATION | Human Rt. (HU) | 2004-10-20 | — | — | EP | claimed |
| WO-2003039559-A1 | PHARMACEUTICAL COMBINATONS COMPRISING A FUNGICIDE, A BACTERIOSTATIC SULPHONAMIDE AND AN ANTIBACTERIAL COMPOUND FOR TOPICAL APPLICATION | HUMAN RT. (HU) | 2003-05-15 | — | — | WO | claimed |
| EP-2068934-B1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | BOTTI PAOLO (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| EP-2542696-A1 | BIOMARKERS FOR THERANOSTICS | Caris Life Sciences Luxembourg Holdings (LU) | 2013-01-09 | — | — | EP | disclosed |
| WO-2012115885-A1 | CIRCULATING BIOMARKERS | CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS, S.A.R.L. (LU) | 2012-08-30 | — | — | WO | disclosed |
| WO-2011109440-A1 | BIOMARKERS FOR THERANOSTICS | CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS (LU) | 2011-09-09 | — | — | WO | disclosed |
| US-7811599-B2 | Synergistic water-free carrier dispersion of a fungicide, preferably an azole type, an antibacterial compound preferably of the azalide, linkozamide, polypeptide or erthyromycin-derivative type, and a sparingly water-soluble bacteriostatic sulphonamide; for treatment of skin bearing epithelial lesions | Lukacs, Karoly (HU) | 2010-10-12 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-1467743-B1 | PHARMACEUTICAL COMBINATIONS COMPRISING A FUNGICIDE, A BACTERIOSTATIC SULPHONAMIDE AND AN ANTIBACTERIAL COMPOUND FOR TOPICAL APPLICATION | LUKACS KAROLY (HU) | 2009-11-04 | — | — | EP | disclosed |
| EP-2068934-A2 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | Botti, Paolo (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008037484-A2 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | BOTTI PAOLO (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20050043222-A1 | Pharmaceutical combinations comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application | LUKACS, KAROLY (HU) | 2005-02-24 | — | — | US | disclosed |
| EP-1467743-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A FUNGICIDE, A BACTERIOSTATIC SULPHONAMIDE AND AN ANTIBACTERIAL COMPOUND FOR TOPICAL APPLICATION | Human Rt. (HU) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003039559-A1 | PHARMACEUTICAL COMBINATONS COMPRISING A FUNGICIDE, A BACTERIOSTATIC SULPHONAMIDE AND AN ANTIBACTERIAL COMPOUND FOR TOPICAL APPLICATION | HUMAN RT. (HU) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | SLC2A1, SLC2A4, SLC2A9 | ALDH1A1 1145/4885CYP3A4 3013/4885SMN1; SMN2 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.